| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-03-17 21:21:10 UTC |
|---|
| Updated at | 2024-09-03 04:17:42 UTC |
|---|
| NP-MRD ID | NP0049975 |
|---|
| Natural Product DOI | https://doi.org/10.57994/1137 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Menatetrenone |
|---|
| Description | Menatetrenone, also known as menaquinone 4 or vitamin K2, belongs to the class of organic compounds known as menaquinones. These are vitamin K2 compounds consisting of a naphtho-1,4-quinone ring system, which is substituted at the 2-position by an isoprenyl side-chain, and usually, at the 3-position by a methyl group. Menatetrenone is an extremely weak basic (essentially neutral) compound (based on its pKa). Menatetrenone exists in all living organisms, ranging from bacteria to humans. Outside of the human body, Menatetrenone is found, on average, in the highest concentration within a few different foods, such as sausages, cold cuts, and eggs and in a lower concentration in pink salmons, empanada, and macaroni and cheeses. Menatetrenone has also been detected, but not quantified in, several different foods, such as common pea, other soy products, feijoa, alaska pollocks, and enokitakes. This could make menatetrenone a potential biomarker for the consumption of these foods. Menatetrenone was first documented in 2013 (PMID: 22692649). Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma (PMID: 23169578) (PMID: 23346882) (PMID: 23702931) (PMID: 23832575) (PMID: 24085302) (PMID: 24138531). |
|---|
| Structure | [H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+ |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Methyl-3-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-naphthoquinone | ChEBI | | 2-Methyl-3-geranylgeranyl-1,4-naphthoquinone | ChEBI | | 2-Methyl-3-trans-tetraprenyl-1,4-naphthoquinone | ChEBI | | Menaquinone 4 | ChEBI | | Menaquinone K4 | ChEBI | | Menaquinone-4 | ChEBI | | Menatetrenona | ChEBI | | Menatetrenonum | ChEBI | | MK-4 | ChEBI | | MK4 | ChEBI | | Vitamin K2 | ChEBI | | Vitamin MK 4 | ChEBI | | 2-Methyl-3-all-trans-tetraprenyl-1,4-naphthoquinone | HMDB | | Vitamin K2(20) | HMDB | | Kefton-2 | HMDB | | (e,e,e)-Isomer OF menatetrenone | HMDB | | Vitamin MK-4 | HMDB | | Vitamin K 2 | MeSH | | Vitamin K quinone | MeSH | | Menaquinone | MeSH | | Menaquinones | MeSH |
|
|---|
| Chemical Formula | C31H40O2 |
|---|
| Average Mass | 444.6590 Da |
|---|
| Monoisotopic Mass | 444.30283 Da |
|---|
| IUPAC Name | 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1,4-dihydronaphthalene-1,4-dione |
|---|
| Traditional Name | menatetrenone |
|---|
| CAS Registry Number | 863-61-6 |
|---|
| SMILES | [H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C |
|---|
| InChI Identifier | InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+ |
|---|
| InChI Key | DKHGMERMDICWDU-GHDNBGIDSA-N |
|---|
| Experimental Spectra |
|---|
|
| | Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
|---|
| HSQC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2023-10-20 | View Spectrum | | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2023-10-20 | View Spectrum | | COSY NMR | [1H, 1H] NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2023-10-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2023-10-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2023-10-20 | View Spectrum |
| | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as menaquinones. These are vitamin K2 compounds consisting of a naphtho-1,4-quinone ring system, which is substituted at the 2-position by an isoprenyl side-chain, and usually, at the 3-position by a methyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Prenol lipids |
|---|
| Sub Class | Quinone and hydroquinone lipids |
|---|
| Direct Parent | Menaquinones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Menaquinone
- Diterpenoid
- Naphthoquinone
- Naphthalene
- Aryl ketone
- Quinone
- Benzenoid
- Ketone
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Suzuki K, Tsuji S, Fukushima Y, Nakase T, Hamada M, Tomita T, Yoshikawa H: Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK(2)) in postmenopausal RA patients. Mod Rheumatol. 2013 May;23(3):450-5. doi: 10.1007/s10165-012-0678-x. Epub 2012 Jun 13. [PubMed:22692649 ]
- Nickerson ML, Bosley AD, Weiss JS, Kostiha BN, Hirota Y, Brandt W, Esposito D, Kinoshita S, Wessjohann L, Morham SG, Andresson T, Kruth HS, Okano T, Dean M: The UBIAD1 prenyltransferase links menaquinone-4 [corrected] synthesis to cholesterol metabolic enzymes. Hum Mutat. 2013 Feb;34(2):317-29. doi: 10.1002/humu.22230. Epub 2012 Nov 27. [PubMed:23169578 ]
- Iwamoto J, Sato Y: Menatetrenone for the treatment of osteoporosis. Expert Opin Pharmacother. 2013 Mar;14(4):449-58. doi: 10.1517/14656566.2013.763796. Epub 2013 Jan 25. [PubMed:23346882 ]
- Koitaya N, Sekiguchi M, Tousen Y, Nishide Y, Morita A, Yamauchi J, Gando Y, Miyachi M, Aoki M, Komatsu M, Watanabe F, Morishita K, Ishimi Y: Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women. J Bone Miner Metab. 2014 Mar;32(2):142-50. doi: 10.1007/s00774-013-0472-7. Epub 2013 May 24. [PubMed:23702931 ]
- Inoue K, Hamano T, Nango N, Matsui I, Tomida K, Mikami S, Fujii N, Nakano C, Obi Y, Shimomura A, Kusunoki Y, Rakugi H, Isaka Y, Tsubakihara Y: Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone Miner Metab. 2014 May;32(3):271-80. doi: 10.1007/s00774-013-0485-2. Epub 2013 Jul 6. [PubMed:23832575 ]
- Hirota Y, Tsugawa N, Nakagawa K, Suhara Y, Tanaka K, Uchino Y, Takeuchi A, Sawada N, Kamao M, Wada A, Okitsu T, Okano T: Menadione (vitamin K3) is a catabolic product of oral phylloquinone (vitamin K1) in the intestine and a circulating precursor of tissue menaquinone-4 (vitamin K2) in rats. J Biol Chem. 2013 Nov 15;288(46):33071-80. doi: 10.1074/jbc.M113.477356. Epub 2013 Sep 30. [PubMed:24085302 ]
- Edson KZ, Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, Rettie AE: Cytochrome P450-dependent catabolism of vitamin K: omega-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry. 2013 Nov 19;52(46):8276-85. doi: 10.1021/bi401208m. Epub 2013 Nov 7. [PubMed:24138531 ]
- Guralp O, Erel CT: Effects of vitamin K in postmenopausal women: mini review. Maturitas. 2014 Mar;77(3):294-9. doi: 10.1016/j.maturitas.2013.11.002. Epub 2013 Nov 27. [PubMed:24342502 ]
- Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW: Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging. 2014;9:121-7. doi: 10.2147/CIA.S54107. Epub 2014 Jan 8. [PubMed:24426779 ]
- Shearer MJ, Newman P: Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res. 2014 Mar;55(3):345-62. doi: 10.1194/jlr.R045559. Epub 2014 Jan 31. [PubMed:24489112 ]
- Rodbotten R, Gundersen T, Vermeer C, Kirkhus B: Vitamin K2 in different bovine muscles and breeds. Meat Sci. 2014 May;97(1):49-53. doi: 10.1016/j.meatsci.2014.01.005. Epub 2014 Jan 22. [PubMed:24508562 ]
- Gentili A, Cafolla A, Gasperi T, Bellante S, Caretti F, Curini R, Fernandez VP: Rapid, high performance method for the determination of vitamin K(1), menaquinone-4 and vitamin K(1) 2,3-epoxide in human serum and plasma using liquid chromatography-hybrid quadrupole linear ion trap mass spectrometry. J Chromatogr A. 2014 Apr 18;1338:102-10. doi: 10.1016/j.chroma.2014.02.065. Epub 2014 Feb 28. [PubMed:24630057 ]
- Hanzawa F, Sakuma E, Nomura S, Uchida T, Oda H, Ikeda S: Excess alpha-tocopherol decreases extrahepatic phylloquinone in phylloquinone-fed rats but not menaquinone-4 in menaquinone-4-fed rats. Mol Nutr Food Res. 2014 Aug;58(8):1601-9. doi: 10.1002/mnfr.201300710. Epub 2014 Apr 16. [PubMed:24737747 ]
- Iwamoto J: Vitamin K(2) therapy for postmenopausal osteoporosis. Nutrients. 2014 May 16;6(5):1971-80. doi: 10.3390/nu6051971. [PubMed:24841104 ]
- Iwamoto J, Sato Y, Matsumoto H: Vitamin K2 improves femoral bone strength without altering bone mineral density in gastrectomized rats. J Nutr Sci Vitaminol (Tokyo). 2014;60(2):71-7. doi: 10.3177/jnsv.60.71. [PubMed:24975215 ]
|
|---|